Clinical effect of alprostadil combined with Shenkang treatment of chronic renal failure in elderly patients
10.3760/cma.j.issn.0254-9026.2013.12.012
- VernacularTitle:前列地尔联合肾康注射液治疗老年人慢性肾衰竭的临床疗效分析
- Author:
Jintu WU
- Publication Type:Journal Article
- Keywords:
Kidney failure,chronic;
Alprostadil
- From:
Chinese Journal of Geriatrics
2013;32(12):1303-1304
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of alprostadil combined with Shenkang on chronic renal failure in elderly patients.Methods 84 elderly patients with chronic renal failure were chosen from Feb.2010 to Feb.2013,and divided into treatment group and control group.The patients were treated with alprostadil combined with Shenkang in treatment group,and were treated with Shenkang in control group.Clinical efficacy was compared between the two groups.Results In treatment group,clinical efficacy was markedly effective in 20 cases,effective in 12 cases and ineffective in 10 cases,and the total effective rate was 80.0％.In control group,clinical efficacy was markedly effective in 17 cases,effective in 12 cases and ineffective in 13 cases,and the total effective rate was 69.0％.There was no significant difference in total effective rate between groups (x2 =0.539,P＞0.05).There were no differences in the levels of serum creatinine clearance rate (Ccr) and creatinine (Scr),24 h urine protein (24-Upro) and blood urea nitrogen (BUN) between the two groups before treatment (all P＞0.05).After treatment,Ccr level was higher in treatment group than in control group (t=1.931,P＜0.05),and Scr,24-Upro and BUN levels were lower in treatment group than in control group (t=1.999,1.684,2.246,respectively,all P＜0.05).Conclusions Alprostadil combined with Shenkang can effectively improve the related renal function index in the treatment of elderly chronic renal failure,which is worthy of clinical application.
